

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for delivery of a chemical or biological entity to a target tissue or cellular surface of a patient comprising:
binding a molecule to said tissue or cellular surface, wherein said molecule comprises at least one reactive group that reacts with groups present on said surface, and at least one signaling molecule;
attaching said chemical or biological entity to said signaling molecule by means of a recognition molecule, wherein said recognition molecule is specific for said signaling molecule, wherein the recognition molecule and the signaling molecule have an affinity for each other; and
wherein said reactive group binds ionically, covalently, non-covalently or by hydrogen bonding to said tissue or cellular surface.
2. (original): The method of Claim 1, wherein said molecule further comprises a polymer that masks adhesive information inherent to the tissue or cellular surface.
3. (currently amended): The method of Claim 1, wherein said tissue is vascular tissue and where the tissue or cellular surface provides a target for subsequent delivery of the chemical or biological entity.
4. (canceled)
5. (currently amended): The method of Claim 1, wherein said reactive group is selected from the group consisting of an ester, anhydride, isocyanate, aldehyde, tosylate, tresylate, epoxide, or maleimide and a N-hydroxy-succinimide.
6. (withdrawn): The method of Claim 1, wherein the reactive group is a cycloester, cycloanhydride or isocyanate.
7. (original): The method of Claim 1, wherein the reactive group is N-hydroxy-succinimide.

8. (original): The method of Claim 2, wherein the polymer is polyethylene glycol.
9. (original): The method of Claim 8, wherein the reactive group is N-hydroxy-succinimide.
10. (original): The method of Claim 1, wherein delivery is of a chemical entity.
11. (currently amended): The method of Claim 10, wherein said chemical entity is a pharmaceutical agent in a form selected from the group consisting of molecular, liposomal, micellar and solid particulate.
12. (original): The method of Claim 11, wherein said pharmaceutical agent is an anti-thrombotic agent, an antimitotic agent, or a chemotherapeutic agent.
13. (withdrawn): The method of Claim 10, wherein said chemical agent is a contrast or imaging agent.
14. (withdrawn): The method of Claim 1, wherein delivery is of a biological entity.
15. (withdrawn): The method of Claim 14, wherein said biological entity is a modified or unmodified cell.
16. (withdrawn): The method of Claim 15, wherein said biological entity is a chemically modified cell.
17. (withdrawn): The method of Claim 15, wherein said biological entity is a genetically modified cell.
18. (withdrawn): The method of Claim 1, wherein delivery is of a viral vector, non-viral vector or naked nucleic acid sequence.
19. (currently amended): The method of Claim 1, wherein said signaling molecule/~~binding-recognition~~ molecule combination is selected from the group consisting of biotin/avidin; ligand/receptor; antibody/antigen; primary antibody/secondary antibody; protein A/fc IgG1; and protein c/fc IgG1.
20. (original): The method of Claim 1, wherein said delivery steps can be effected under conditions tolerable *in vivo*.

21. (withdrawn): A tissue surface that has been modified by binding to the surface a molecule, wherein said molecule comprises at least one reactive group that reacts with groups present on said surface, and at least one signaling molecule.

22. (withdrawn): A cellular surface that has been modified by binding to the surface a molecule, wherein said molecule comprises at least one reactive group that reacts with groups present on said surface, and at least one signaling molecule.

23. (new): The method of Claim 1, wherein said delivery steps can be effected in from about 1 to about 2 minutes, and wherein the groups present on the tissue or cellular surface are selected from the group consisting of amines and hydroxyl groups.

24. (new): The method of Claim 1, wherein said reactive group is selected from the group consisting of an ester, anhydride, isocyanate, aldehyde, tosylate, tresylate, epoxide, maleimide and a N-hydroxy-succinimide, and mixtures thereof and the signaling molecule/recognition molecule is selected from the group consisting of biotin/avidin; ligand/receptor; antibody/antigen; primary antibody/secondary antibody; protein A/c IgG1; and protein c/fc IgG1.

25. (new): The method of Claim 1, wherein the chemical or biological entity is a microbubble ultrasound contrasting agent, which can be delivered locally.

26. (new): The method of Claim 1, wherein the delivery of the chemical or biological entity is local or systemic.

27. (new): The method of Claim 1, wherein the delivery of the chemical or biological entity is local.

28. (new): The method of Claim 1, wherein the reactive group binds covalently.

29. (new): The method of Claim 1, wherein the signaling molecule includes any group that will function to signal the recognition molecule absent compatibility problems.